Published in J Clin Oncol on March 21, 2011
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A (2013) 2.09
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol (2011) 1.79
Circulating tumor cells in lung cancer: detection methods and clinical applications. Lung (2015) 1.63
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol (2015) 1.63
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol (2012) 1.45
Circulating Aneuploid Cells Detected in the Blood of Patients with Infectious Lung Diseases. Korean J Thorac Cardiovasc Surg (2017) 1.38
High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol (2012) 1.37
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol (2014) 1.34
Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol (2010) 1.29
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One (2013) 1.21
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS One (2013) 1.15
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One (2014) 1.14
Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol (2013) 1.14
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget (2014) 1.08
Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One (2013) 1.06
Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med (2013) 1.05
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One (2013) 1.04
Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer (2012) 1.02
The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep (2015) 1.02
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann Oncol (2015) 0.99
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. Front Oncol (2014) 0.97
High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer (2015) 0.96
The promise of circulating tumor cell analysis in cancer management. Genome Biol (2014) 0.95
Filtration parameters influencing circulating tumor cell enrichment from whole blood. PLoS One (2013) 0.94
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment. Cancers (Basel) (2014) 0.94
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer (2015) 0.94
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med (2014) 0.94
Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One (2015) 0.93
The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clin Exp Metastasis (2012) 0.93
Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn (2012) 0.92
Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis (2013) 0.91
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer (2016) 0.90
The biology of circulating tumor cells. Oncogene (2015) 0.90
Sensitive and direct detection of circulating tumor cells by multimarker µ-nuclear magnetic resonance. Neoplasia (2012) 0.89
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. PLoS One (2014) 0.88
Interpretation of changes in circulating tumor cell counts. Transl Oncol (2012) 0.88
Circulating tumor cells in the central and peripheral venous compartment - assessing hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Onco Targets Ther (2014) 0.88
An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One (2013) 0.88
Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci U S A (2016) 0.87
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol (2014) 0.86
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One (2014) 0.85
Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer. Front Oncol (2015) 0.85
Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS One (2014) 0.85
Progress in using circulating tumor cell information to improve metastatic breast cancer therapy. J Oncol (2013) 0.84
Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection. PLoS One (2016) 0.84
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PLoS One (2014) 0.84
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Oncologist (2016) 0.83
Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer. PLoS One (2013) 0.83
Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha. Biomark Insights (2016) 0.82
Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer (2014) 0.82
Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis. Cancers (Basel) (2013) 0.82
Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. J Invest Dermatol (2015) 0.81
Method validation of circulating tumour cell enumeration at low cell counts. BMC Cancer (2013) 0.81
Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PLoS One (2015) 0.81
Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study. PLoS One (2013) 0.81
Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform. Lab Chip (2014) 0.81
Characterization of different CTC subpopulations in non-small cell lung cancer. Sci Rep (2016) 0.81
Metastasis: an early event in cancer progression. J Cancer Res Clin Oncol (2016) 0.81
High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. PLoS One (2015) 0.81
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res (2016) 0.80
High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. Oncotarget (2016) 0.80
Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit Rev Clin Lab Sci (2015) 0.80
Nanotechnology for enrichment and detection of circulating tumor cells. Nanomedicine (Lond) (2015) 0.80
Circulating tumor cells as lung cancer biomarkers. J Thorac Dis (2012) 0.80
Single-cell analyses of circulating tumor cells. Cancer Biol Med (2015) 0.80
Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget (2016) 0.80
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. Front Oncol (2015) 0.79
TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer. Oncotarget (2015) 0.79
Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int J Clin Exp Pathol (2014) 0.79
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study. Ann Oncol (2016) 0.79
Isolation and characterization of circulating tumor cells from human gastric cancer patients. J Cancer Res Clin Oncol (2014) 0.79
A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. J Transl Med (2014) 0.78
Silver Nanoscale Hexagonal Column Chips for Detecting Cell-free DNA and Circulating Nucleosomes in Cancer Patients. Sci Rep (2015) 0.78
Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. PLoS One (2015) 0.78
Detection of circulating tumor cells. Scientifica (Cairo) (2014) 0.78
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget (2016) 0.78
Circulating tumor-derived biomarkers in lung cancer. J Thorac Dis (2012) 0.78
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. PLoS One (2015) 0.78
Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods (2015) 0.78
Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. J Thorac Oncol (2016) 0.78
Circulating tumor cells: clinical validity and utility. Int J Clin Oncol (2017) 0.77
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget (2016) 0.77
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Int J Cancer (2015) 0.77
Biology and clinical relevance of circulating tumour cells. J Thorac Dis (2012) 0.77
Investigating CTCs in NSCLC-a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer. J Thorac Dis (2016) 0.77
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. PLoS One (2016) 0.77
MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment. Sci Rep (2016) 0.77
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol (2012) 3.51
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med (2010) 2.94
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol (2012) 2.81
Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol (2011) 2.76
Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem (2008) 2.40
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
MRI in ALS: corticospinal tract hyperintensity. Neurology (2003) 2.24
Evidence-based assessment: evaluation of the formocresol versus ferric sulfate primary molar pulpotomy. Pediatr Dent (2004) 2.22
Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 2.10
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol (2012) 1.91
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther (2010) 1.85
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res (2006) 1.80
Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol (2004) 1.77
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 1.75
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.68
Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol (2005) 1.64
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
Where next for gefitinib in patients with lung cancer? Lancet Oncol (2006) 1.58
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer (2011) 1.53
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst (2002) 1.52
Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord (2005) 1.44
Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene (2004) 1.41
Echocardiography in the detection of cardioembolism in a stroke population. J Clin Neurosci (2010) 1.38
Multiplexed assays for detection of mutations in PIK3CA. Clin Chem (2008) 1.36
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs (2011) 1.34
Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol (2010) 1.29
Mitochondrial membrane permeabilisation by Bax/Bak. Biochem Biophys Res Commun (2003) 1.27
Update on tubulin-binding agents. Pathol Biol (Paris) (2006) 1.26
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom (2010) 1.24
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013) 1.24
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol (2009) 1.19
Quantitative proteomics analysis demonstrates post-transcriptional regulation of embryonic stem cell differentiation to hematopoiesis. Mol Cell Proteomics (2007) 1.19
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
Drug target prediction and repositioning using an integrated network-based approach. PLoS One (2013) 1.18
Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. J Biol Chem (2003) 1.17
Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord (2004) 1.17
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem (2004) 1.16
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemother Pharmacol (2007) 1.16
Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer (2011) 1.15
Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res (2004) 1.15
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res (2004) 1.13
Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis (2012) 1.11
Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood (2003) 1.11
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther (2008) 1.10
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs (2010) 1.10
Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust (2012) 1.10
Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust (2007) 1.09
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord (2005) 1.09
Generation of cells expressing improved doxycycline-regulated reverse transcriptional transactivator rtTA2S-M2. Nat Protoc (2006) 1.08
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia (2007) 1.07
Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal Chem (2011) 1.07